Skip to main content
You're viewing the free public version. Create a free account for full research and member tools. Join free
Research Abstract Animal Study

Electroacupuncture reduces amyloid beta accumulation and improves cerebral ischemia-induced cognitive impairment.

Electroacupuncture reduces amyloid beta accumulation and improves cerebral ischemia-induced cognitive impairment in a N6-methyladenosine-dependent manner.

0:00 / 0:00
0:00 / 0:00

Sign in to access this feature

Create a free account or sign in to use AI summaries, listen to articles, download PDFs, and save to your library.

122 views
Share:

Abstract

Electroacupuncture (EA) has been widely used in the clinical treatment of cognitive impairment after cerebral ischemia (CI) in China, but the specific molecular mechanism is not fully understood yet. In this study, permanent middle cerebral artery occlusion (pMCAO) model mice were administrated with EA therapy, Morris water maze (MWM) test was used for evaluation of cognitive function, Nissl staining was employed to quantify surviving neurons in the hippocampus, and enzyme-linked immunosorbent assay (ELISA) was utilized to detect the levels of amyloid beta (Aβ). The results showed that EA treatment obviously improved learning and memory abilities in the mice with pMCAO, inhibited neuronal loss in the hippocampus, and reduced the levels of Aβ40 and Aβ42. Meanwhile, we observed that METTL3 expression and total N6-methyladenosine (m6A) levels were significantly increased in the hippocampal tissues of pMCAO mice, which were reduced by EA therapy. Then, hippocampal neuronal cell line HT22 was induced by oxygen-glucose deprivation (OGD) to verify the molecular regulatory mechanism in vitro, and we found that METTL3 upregulated BACE1 expression in OGD-induced HT22 cells through promoting m6A enrichment on BACE1 mRNA, thus facilitating Aβproduction and cell apoptosis of OGD-induced HT22 cells. Finally, through in vivo functional recovery experiments, we demonstrated that EA therapy restrained the METTL3/BACE1 axis to alleviate Aβaccumulation and cognitive dysfunction in pMCAO model mice. In summary, our data reveals that the m6A-modified BACE1 pathway is one of the molecular targeting mechanisms for EA treatment in cognitive impairment after CI.

Affiliation

Jianbo Yang

External References

PubMed ID:
41524945

Comments

Sign in or create a free account to join the conversation.

Sign in to comment

Be the first to comment.

More Research Abstracts

View All Abstracts

Trusted By Professionals and Teams:

The National Health Federation
Stand For Health Freedom
Global Healing Institute
Global Wellness Forum
MAHA Action
Myers Detox
Natural News
Mercola.com

Unlock Evidence-Based Health Research

Join 500,000+ members accessing 10,000+ natural health topics.

Subscribe to our informative Newsletter & Receive

Cancer Fighting Foods Ebook

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.